Pepticom is delighted to present our latest article, published in the Journal of Immunology, on the subject of Computationally Designed Bispecific MD2/CD14 Binding Peptides Show TLR4 Agonist Activity. To the best of our knowledge, this is the first example of using Artificial Intelligence for the discovery of novel cyclic peptides; the discovery effort yielded 53 novel bi-specific cyclic ligands for TLR4 co-receptors CD14 and MD2. The 53 discovered peptides are of diverse chemistry and include linear and cyclic peptides with natural and non-natural amino acids (including all D amino acids). The discovered peptides position Pepticom’s platform at the forefront of peptide discovery today. Link to the article: https://lnkd.in/gt-4AWH
